CardieX Gelecekteki Büyüme

Future kriter kontrolleri 5/6

CardieX kazanç ve gelirin sırasıyla yıllık 90.7% ve 54.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 120.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 1% olacağı tahmin edilmektedir.

Anahtar bilgiler

90.7%

Kazanç büyüme oranı

120.1%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	16.1%
Gelir büyüme oranı	54.8%
Gelecekteki özkaynak getirisi	1.0%
Analist kapsamı	Low
Son güncelleme	06 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

ASX:CDX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	70	40	40	40	1
6/30/2026	51	24	24	24	1
6/30/2025	17	-3	-4	-4	1
6/30/2024	13	-7	-8	-8	N/A
3/31/2024	13	-8	-7	-7	N/A
12/31/2023	14	-9	-5	-5	N/A
9/30/2023	10	-14	-9	-9	N/A
6/30/2023	6	-19	-12	-12	N/A
3/31/2023	5	-16	-11	-11	N/A
12/31/2022	4	-14	-10	-10	N/A
9/30/2022	4	-13	-10	-9	N/A
6/30/2022	5	-12	-10	-9	N/A
3/31/2022	5	-11	-9	-8	N/A
12/31/2021	5	-10	-8	-8	N/A
9/30/2021	5	-7	-6	-6	N/A
6/30/2021	6	-5	-4	-4	N/A
3/31/2021	5	-4	-3	-3	N/A
12/31/2020	5	-3	-2	-2	N/A
9/30/2020	5	-3	-2	-2	N/A
6/30/2020	5	-3	-2	-2	N/A
3/31/2020	5	-3	-2	-2	N/A
12/31/2019	5	-4	-2	-2	N/A
9/30/2019	5	-3	-2	-2	N/A
6/30/2019	5	-3	-3	-2	N/A
3/31/2019	5	-3	-3	-3	N/A
12/31/2018	4	-3	-3	-3	N/A
9/30/2018	4	-3	-2	-2	N/A
6/30/2018	4	-3	-2	-2	N/A
3/31/2018	5	-3	N/A	-2	N/A
12/31/2017	5	-4	N/A	-2	N/A
9/30/2017	5	-4	N/A	-3	N/A
6/30/2017	5	-4	N/A	-3	N/A
3/31/2017	5	-4	N/A	-4	N/A
12/31/2016	5	-4	N/A	-4	N/A
9/30/2016	5	-5	N/A	-5	N/A
6/30/2016	5	-5	N/A	-5	N/A
3/31/2016	5	-4	N/A	-4	N/A
12/31/2015	4	-4	N/A	-4	N/A
9/30/2015	5	-3	N/A	-3	N/A
6/30/2015	5	-1	N/A	-2	N/A
3/31/2015	5	-2	N/A	-2	N/A
12/31/2014	5	-2	N/A	-3	N/A
9/30/2014	5	-2	N/A	-2	N/A
6/30/2014	5	-3	N/A	-1	N/A
3/31/2014	6	-2	N/A	0	N/A
12/31/2013	6	0	N/A	1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CDX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: CDX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: CDX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: CDX şirketinin gelirinin (yıllık 54.8% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: CDX şirketinin gelirinin (yıllık 54.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CDX 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 1 %).

CardieX Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

New minor risk - Share price stability

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin